Table 3.

Comparison of the positivity of TSAs in patients with and without anti-SSA, anti-SSB, and ANA.

Antibodies	Anti-SSA+ (n = 108)	Anti-SSA- (n = 29)	P	Anti-SSB+ (n = 57)	Anti-SSB- (n = 80)	P	ANA+ (n = 118)	ANA- (n = 19)	P
Anti-CA6+	37 (34.3%)	14 (48.3%)	0.166	20 (35.1%)	31 (38.8%)	0.662	44 (37.3%)	7 (36.8%)	0.970
Anti-SP1+	10 (9.3%)	4 (13.8%)	0.495	7 (12.3%)	7 (8.8%)	0.501	12 (10.2%)	2 (10.5%)	1.000
Anti-PSP+	21 (19.4%)	14 (48.3%)	0.002∗	13 (22.8%)	22 (27.5%)	0.960	29 (24.6%)	6 (31.6%)	0.573
TSA+	44 (40.7%)	18 (62.1%)	0.04∗	23 (40.4%)	39 (48.8%)	0.986	53 (44.9%)	9 (47.4%)	0.728

^∗ P < 0.05.